Study: Stem cells may open door to new tools for colorectal cancer detection, treatment

NewsGuard 100/100 Score

Colorectal cancer cells trigger a set of genes similar to those found in intestinal stem cells, scientists at the Institute for Research in Biomedicine (IRB Barcelona) have found. The team of researchers, led by ICREA researcher Eduard Batlle, propose that patients with colorectal cancer undergo genetic tests of their intestinal epithelium in order to predict a higher risk of relapse. The results of the study, published online this week in Cell Stem Cell, offer new possibilities for diagnosing and treating the disease.

Colon cancer is the second cause of death by cancer worldwide. Current treatment for the disease normally involves a combination of surgery and chemotherapy. Most patients who are treated successfully go into remission, but nearly 40% relapse within months or years, when the cancer returns or metastasizes. "This shows us that there are cells within the tumour that regenerate the disease," says Batlle, "but we still know very little about the biological reasons why."

Cancer's "hard core"

The study conducted by Anna Merlos-Su-rez and other researchers in Batlle's team has uncovered a close relation between intestinal stem cells (non-specialised cells that generate all cells within the intestine) and colorectal cancer. The researchers compared genes that are activated in cells from a healthy intestine - both stem cells and specialised cells - with the genes that are activated in tumour cells taken from patients. "Our results show that patients with colon cancer have a set of genes activated that is very similar to the set activated in stem cells. The more genes they have activated in common, the more likely it is that the patient's cancer will spread and relapse.

These stem cell genes become activated in a subset of cells in the tumour, called "tumour stem cells". When Batlle's team transplanted these cells into mice, tumours formed. Their results add to the growing hypothesis that cancer organizes itself hierarchically, in such a way that only specific cells, "tumour stem cells", are able to initiate and propagate the cancer.

What is it about stem cells that allows them to promote cancer? By definition, stem cells renew tissues, including in this case the intestinal epithelium, and can produce up to 5 grams of intestinal epithelial cells each day. Scientists believe that tumours may exploit the capacity of these cells to renew indefinitely in order to grow and spread. Furthermore, while the majority of cells have an average lifespan of days, as in the case of intestinal epithelial cells, or even months, stem cells survive for many years, increasing the probability that their DNA will accumulate damage and that they will turn cancerous.

One of the biggest hurdles that oncologists face is a lack of tools to identify which patients have a higher risk of relapse. Discovering a close relation between intestinal stem cells and the propagation of cancer is a clear breakthrough in this respect. The hypothesis that colorectal cancer requires a specific type of cell to develop and thrive has also been demonstrated in other types of cancer, including gliomas, some types of lymphoma or breast cancer. This finding opens the door for the development of treaments aimed at these new targets in the fight against cancer: tumour stem cells.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer